Fat-loss peptide

Adipotide

Also known as FTPP

An aggressive, short-cycle fat-loss peptide for resistant cases.

Early / anecdotal

Overview

Adipotide - also known as FTPP - is an experimental fat-loss peptide that takes a mechanistically different approach from every other agent on this list. Rather than suppressing appetite or improving fat-cell metabolism, it works by targeting the blood supply that feeds fat tissue. In preclinical studies, disrupting this blood supply triggered programmed death of fat cells in the targeted area. This is a more aggressive mechanism than GLP-1 agonists or metabolic compounds, which is why adipotide is described as suited to resistant cases - situations where more conventional approaches have not achieved the desired fat loss. Adipotide is used in short, closely supervised cycles. Unlike most peptides on this list where a general dose range can be stated, dosing for adipotide is set entirely at consult - there is no general patient-facing range appropriate to share outside of a clinical discussion. Injection frequency and timing also follow the specific protocol established at your consult. The most significant safety concern comes from animal studies showing kidney effects. This is why adipotide is used cautiously and rarely - kidney function monitoring is a component of supervised protocols. It is classified as experimental with limited human data, and evidence is anecdotal rather than clinical or emerging from human trials. Adiopotide is not appropriate during pregnancy. It is not currently FDA-approved. Given its experimental status and the kidney-monitoring requirement, this is one of the peptides where the clinician consultation is especially important. All dosing, protocol structure, and safety monitoring are set with a licensed provider in the PepDepo network at consult.

At a glance

Route

SC injection

Dose

Set at consult

Frequency

Short supervised cycles

Timing

Per protocol

Cycle

Short, closely monitored

Safety

Kidney effects seen in animal studies; used cautiously and rarely.

Regulatory: Experimental; limited human data.

Not appropriate if: pregnant.

Questions

How does adipotide work differently from GLP-1 agents?⌄

GLP-1 agents reduce appetite so you eat less. Adipotide works by targeting the blood vessels that supply fat tissue - disrupting that supply triggers fat-cell death in preclinical work. It acts on the fat itself, not on hunger signals.

What is the main safety concern?⌄

Animal studies showed kidney effects with adipotide. This is why it is used cautiously, rarely, and only in closely monitored protocols that include kidney function tracking.

Who is it typically used for?⌄

It is described as suited to resistant fat-loss cases - people for whom more conventional approaches have not produced the desired result and who are willing to do a closely supervised short cycle.

How is it taken?⌄

Subcutaneous injection in short, supervised cycles. Frequency, timing, and dose are set entirely at consult - no general dose range is given outside of a clinical conversation.

Is it FDA-approved or investigational?⌄

It is classified as experimental with limited human data. It is not FDA-approved.

Are there contraindications?⌄

Adipotide is not appropriate during pregnancy. The kidney-effects signal from animal studies means anyone with existing kidney concerns should discuss that thoroughly with their clinician before considering it.

Want a personalized protocol?

Exact dosing is set with a licensed provider in the PepDepo network. This page is education, not a prescription.

Book a consult

Education only, not medical advice. Peptides discussed are for informational purposes and many are not FDA-approved. Eligibility, prescribing, compounding, and dispensing are handled by appropriately licensed entities. Exact protocols and dosing are set with a licensed provider in the PepDepo network at consult. Content is pending clinical review.